5 years of historical data (2020–2024) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Scilex Holding Company currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 77.8x P/FCF, 1350% above the 5-year average of 5.4x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $104M | $266M | $536M | $1.3B | — |
| Enterprise Value | $1.5B | $138M | $390M | $535M | $1.5B | — |
| P/E Ratio → | -0.42 | — | — | — | — | — |
| P/S Ratio | 26.58 | 1.83 | 5.69 | 14.08 | 42.59 | — |
| P/B Ratio | — | — | — | 14.78 | — | — |
| P/FCF | 77.75 | 5.36 | — | — | — | — |
| P/OCF | 77.75 | 5.36 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.45 | 8.35 | 14.06 | 47.39 | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | 7.15 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Scilex Holding Company earns an operating margin of -147.4%. Operating margins have compressed from -133.1% to -147.4% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 70.5% | 70.5% | 66.5% | 71.6% | 88.4% | 90.9% |
| Operating Margin | -147.4% | -147.4% | -225.6% | -133.1% | -114.4% | -149.7% |
| Net Profit Margin | -128.7% | -128.7% | -244.6% | -61.4% | -282.4% | -201.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | -64.5% | — | — |
| ROA | -75.0% | -75.0% | -121.7% | -28.4% | -110.9% | -58.3% |
| ROIC | — | — | — | -107.1% | — | — |
| ROCE | — | — | — | -121.5% | — | -1165.9% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $35M ($38M total debt minus $3M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.02 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | 1.79 | — | — | — | — |
| Interest Coverage | -42.48 | -42.48 | -98.72 | -5.27 | -3.05 | -2.69 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.16x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.66x to 0.16x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | 0.16 | 0.19 | 0.66 | 0.14 | 0.29 |
| Quick Ratio | 0.15 | 0.15 | 0.17 | 0.63 | 0.12 | 0.27 |
| Cash Ratio | 0.01 | 0.01 | 0.02 | 0.05 | 0.03 | 0.06 |
| Asset Turnover | — | 0.61 | 0.46 | 0.44 | 0.40 | 0.29 |
| Inventory Turnover | 6.85 | 6.85 | 3.72 | 7.84 | 1.42 | 1.88 |
| Days Sales Outstanding | — | 170.55 | 270.16 | 203.79 | 166.29 | 203.35 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Scilex Holding Company does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | 1.3% | 18.7% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 3.8% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 3.8% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $7M | $4M | $4M | $4M | $4M |
Compare SCLX with 5 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SCLXYou | $2B | -0.4 | — | 77.8 | 70.5% | -147.4% | — | — | — |
| ABBV | $410B | 97.1 | 27.0 | 23.0 | 70.0% | 16.2% | 62.2% | 11.1% | 3.9 |
| AMGN | $209B | 27.3 | 12.6 | 25.8 | 82.5% | 40.5% | 106.1% | 20.7% | 2.7 |
| GILD | $186B | 392.0 | 45.7 | 18.0 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
| NVO | $126B | 10.3 | 6.3 | 14.1 | 81.0% | 41.4% | 58.4% | 34.9% | 0.9 |
| BIIB | $28B | 21.7 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 5 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SCLX stacks up against sector leader AbbVie Inc..
Start ComparisonScilex Holding Company's current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Scilex Holding Company is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Scilex Holding Company has 70.5% gross margin and -147.4% operating margin.